Guidotti Luca G, Isogawa Masanori, Chisari Francis V
Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Department of Virology, Nagoya City University Graduate School of Medical Sciences, Kawasumi 1, Mizuho-ku, Nagoya 467-8601, Japan.
Curr Opin Immunol. 2015 Oct;36:61-6. doi: 10.1016/j.coi.2015.06.016. Epub 2015 Jul 15.
Hepatitis B virus (HBV) is a noncytopathic, hepatotropic, double-stranded DNA virus that causes acute and chronic hepatitis. Although HBV does not induce a measurable innate immune response in the infected liver, the outcome of infection is determined by the kinetics, breadth, vigor, trafficking, and effector functions of HBV-specific adaptive T cell responses, and the development of neutralizing antibodies. Dysregulation of one or more of these events leads to persistent HBV infection and a variably severe chronic necroinflammatory liver disease that fosters the development of hepatocellular carcinoma. Deeper understanding of the mechanisms responsible for immunological tolerance to HBV is needed in order to devise immunotherapeutic strategies to cure chronic HBV infection and prevent its life-threatening sequelae.
乙型肝炎病毒(HBV)是一种非细胞病变性、嗜肝性双链DNA病毒,可引起急性和慢性肝炎。虽然HBV在受感染的肝脏中不会引发可测量的先天性免疫反应,但感染的结果取决于HBV特异性适应性T细胞反应的动力学、广度、活力、迁移和效应功能,以及中和抗体的产生。这些事件中一个或多个的失调会导致HBV持续感染以及程度各异的严重慢性坏死性炎症性肝病,进而促进肝细胞癌的发生。为了设计出治愈慢性HBV感染并预防其危及生命后果的免疫治疗策略,需要更深入地了解对HBV免疫耐受的机制。